What is the RPG Life Sciences PE ratio today?
RPG Life Sciences' PE ratio is 45.4 at the 29 October 2026 close (₹3,003.80 a share): a market capitalisation of ₹4,968 crore divided by consolidated net profit attributable to shareholders of ₹109 crore over the last four quarters (Q3 FY26 to Q2 FY27). On FY26 net profit attributable to shareholders (₹115 crore) it is 43.1.
What is the RPG Life Sciences PB ratio (price to book value)?
RPG Life Sciences' price-to-book (PB) ratio is 7.23 at the 29 October 2026 close: a market capitalisation of ₹4,968 crore divided by shareholders' equity (book value) of ₹687 crore on 30 September 2026. That is a book value of ₹415.55 per share against a share price of ₹3,003.80.
What is the RPG Life Sciences net worth?
RPG Life Sciences' net worth — shareholders' equity in its consolidated balance sheet — was ₹687 crore on 30 September 2026. Its market value is a different figure: a market capitalisation of ₹4,968 crore at the 29 October 2026 close.
What is the RPG Life Sciences market cap?
RPG Life Sciences' market capitalisation was ₹4,968 crore at the 29 October 2026 close: 1.65 crore shares at ₹3,003.80 each.
Is RPG Life Sciences debt free?
No. RPG Life Sciences had borrowings of ₹22.3 crore on 30 September 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.03. Its cash and current investments were ₹292 crore, so it held net cash of ₹270 crore.
What is the RPG Life Sciences dividend in 2026 and its record date?
In 2026, RPG Life Sciences has declared one dividend: ₹24 with record date 9 July 2026.
What is the RPG Life Sciences debt to equity ratio?
RPG Life Sciences' debt-to-equity ratio was 0.03 on 30 September 2026: borrowings of ₹22.3 crore against total equity of ₹866 crore.
What is the RPG Life Sciences book value per share?
RPG Life Sciences' book value per share was ₹415.55 on 30 September 2026: shareholders' equity of ₹687 crore divided by the 1.65 crore shares in issue. The share price at the 29 October 2026 close was ₹3,003.80.
What is the RPG Life Sciences revenue and profit in FY26?
In FY26 (April 2025–March 2026), RPG Life Sciences' consolidated net profit attributable to shareholders was ₹115 crore, on revenue from operations of ₹708 crore.
What is the RPG Life Sciences ROE and ROCE?
In FY26, RPG Life Sciences' return on equity (ROE) was 20.3% and its return on capital employed (ROCE) was 21.5%. ROE is net profit attributable to shareholders divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities).
What is the RPG Life Sciences shareholding pattern?
On 30 September 2026, RPG Life Sciences' shares were held by promoters 72.95%, foreign portfolio investors (FII/FPI) 0.87%, domestic institutions (DII) 9.93% (including mutual funds at 0.04%) and retail and other non-institutional investors 16.25%. Over the year, FII holding was down 0.24 percentage points from 1.11% and DII holding was up 3.23 percentage points from 6.70%.
How does the RPG Life Sciences PE ratio compare with its peers?
At the 29 October 2026 closing prices, on FY26 net profit attributable to shareholders, RPG Life Sciences' PE ratio is 43.1, the third highest of the four: Gufic Biosciences 65.4, Gujarat Themis Biosyn 87.7 and Unichem Laboratories 14.1, a peer average of 55.7. Each is the company's market capitalisation at that price divided by its FY26 net profit.
What is the RPG Life Sciences EPS?
RPG Life Sciences' basic earnings per share (EPS) were ₹18.08 in FY26.
What is the RPG Life Sciences promoter holding?
Promoters held 72.95% of RPG Life Sciences on 30 September 2026, unchanged from both the previous quarter and a year earlier, according to the shareholding pattern filed with NSE.
What is the RPG Life Sciences free cash flow?
In FY26, RPG Life Sciences generated ₹56.5 crore of cash from operations and spent ₹65.4 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹8.9 crore. In FY25 it was ₹77.9 crore.
What are the RPG Life Sciences latest quarterly results?
RPG Life Sciences' latest results are for Q2 FY27 (July–September 2026): consolidated net profit attributable to shareholders ₹26.6 crore; revenue from operations ₹212 crore.
When are the RPG Life Sciences next results?
RPG Life Sciences has reported Q2 FY27. Its next results, for Q3 FY27 (October–December 2026), are due by 14 February 2027 under SEBI's 45-day rule; the company notifies the board-meeting date at least two working days before.
How does RPG Life Sciences compare with its peers?
On FY26 consolidated figures, against Gufic Biosciences, Gujarat Themis Biosyn and Unichem Laboratories: RPG Life Sciences' operating margin of 17.8% is the second highest of the four (Gufic Biosciences 12.8%, Gujarat Themis Biosyn 37.8%, Unichem Laboratories 2.7%; peer average 17.7%); its return on equity of 20.3% is the highest of the four (Gufic Biosciences 10.1%, Gujarat Themis Biosyn 17.4%, Unichem Laboratories 9.8%; peer average 12.4%).
RPG Life Sciences vs Gufic Biosciences: how do they compare?
In FY26, RPG Life Sciences earned net profit attributable to shareholders of ₹115 crore on revenue of ₹708 crore, against ₹64.2 crore on ₹944 crore for Gufic Biosciences. RPG Life Sciences' operating margin was 17.8% (Gufic Biosciences 12.8%) and its return on equity 20.3% (Gufic Biosciences 10.1%). At the 29 October 2026 close, RPG Life Sciences' market capitalisation was ₹4,968 crore against ₹4,200 crore for Gufic Biosciences, and its PE ratio on FY26 profit 43.1 against 65.4.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
